Positive impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer

Hyebin Lee, MD¹, Hee Chul Park, MD, PhD¹, Won Park, MD, PhD¹, Doo Ho Choi, MD, PhD¹,
Young-II Kim, MD¹, Young Suk Park, MD, PhD², Joon Oh Park, MD, PhD²,
Ho-Kyung Chun, MD, PhD³, Woo-Yong Lee, MD, PhD³, Hee Cheol Kim, MD, PhD³,
Seong Hyeon Yun, MD, PhD³, Yong Beom Cho, MD, PhD³, Yoon Ah Park, MD³

¹Department of Radiation Oncology, ²Division of Hematology-Oncology, Department of Medicine, ³Department of Surgery,
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Purpose: Although anemia is considered to be a contributor to intra-tumoral hypoxia and tumor resistance to ionizing radiation in cancer patients, the impact of pretreatment anemia on local control after neoadjuvant concurrent chemoradiotherapy (NACRT) and surgery for rectal cancer remains unclear.

Materials and Methods: We reviewed the records of 247 patients with locally advanced rectal cancer who were treated with NACRT followed by curative-intent surgery.

Results: The patients with anemia before NACRT (36.0%, 89/247) achieved less pathologic complete response (pCR) than those without anemia (p = 0.012). The patients with pretreatment anemia had worse 3-year local control than those without pretreatment anemia (86.0% vs. 95.7%, p = 0.005). Multivariate analysis showed that pretreatment anemia (p = 0.035), pathologic tumor and nodal stage (p = 0.020 and 0.032, respectively) were independently significant factors for local control.

Conclusion: Pretreatment anemia had negative impacts on pCR and local control among patients who underwent NACRT and surgery for rectal cancer. Strategies maintaining hemoglobin level within normal range could potentially be used to improve local control in rectal cancer patients.

Keywords: Anemia, Rectal cancer, Neoadjuvant therapy, Concurrent chemoradiotherapy

Introduction

Even though surgical resection is the primary treatment modality for rectal cancer, there is a high incidence of local recurrence after traditional surgery. Since Heald et al. [1] and Heald and Ryall [2] standardized a novel total mesorectal excision (TME) technique for rectal cancer; local failure has decreased from 30% to 10%. In addition, the development of a multidisciplinary team approach has allowed for the further improvement of local control, which has reported up to 2.4–5.6% according to clinical trials [3,4]. Despite these advanced management strategies for rectal cancer, local recurrence still...
remains a major obstacle to get cure from cancer as well as improved quality of life of patients.

Anemia is common condition in cancer patients and is suspected to contribute to intra-tumoral hypoxia, which can attribute to radio-resistance. Previous studies have also revealed that low hemoglobin (Hb) level before or during radiotherapy is an adverse factor for local disease control and patient survival [5]. In addition, a number of studies have shown that anemia is an independent predictive factor for dismal overall survival rates and poor local control at various tumor sites, including head and neck cancer [6,7], lung cancer [8,9], cervical cancer [5], and esophageal cancer [10,11].

However, it is still unclear whether a low Hb level is an adverse factor for local control and survival in patients undergoing neoadjuvant concurrent chemoradiotherapy (NACRT) for locally advanced rectal cancer. In the present study, it was predicted that anemia would represent a major factor influencing the outcome in rectal cancer patients, and here we report the results of this study with an emphasis on the effect of anemia on local control.

Materials and Methods

1. Patient selection
A total of 301 rectal cancer patients were treated with NACRT at Samsung Medical Center between March 2002 and December 2007. Eligibility criteria were as follows: 1) histologically proven, clinical stage II (T3-4 without lymph node metastasis) or III (any T with lymph node involvement) adenocarcinoma of the rectum; 2) absence of distant metastasis at diagnosis; 3) no serious medical condition at diagnosis; 4) no history of previous or any other current malignancies; 5) no history of previous chemotherapy or radiotherapy; and 6) receipt of curative-intent treatment for rectal cancer. Consequently, 247 patients were included in the final analysis.

Hb data were collected from patient medical records. All blood data, which was obtained either just before or at the beginning of radiotherapy, was examined in each patient. Anemia was defined as Hb level of ≤12.0 g/dL in female and ≤13.5 g/dL in male patients according to data from the Third National Health and Nutrition Examination Survey (NHANES III) [12].

2. Treatment modality
Preoperative radiotherapy was delivered to the whole pelvis with a dose of 45 Gy in 25 fractions or 44 Gy in 22 fractions. The radiation field encompassed a volume that included the gross tumor, mesorectum, presacral space, and the regional perirectal, internal iliac, presacral, and distal common iliac lymphatics. Preoperative chemotherapy was delivered concurrently with radiotherapy based on 5-fluorouracil or capecitabine regimens.

All patients received radical surgery 6 to 8 weeks after NACRT completion. Of the 247 patients included in the study, 225 (91.1%) patients received adjuvant chemotherapy.

3. Statistical analysis
Univariate and multivariate analyses were performed using logistic regression analysis to identify the factors associated with pathologic complete response (pCR). Variables with p < 0.1 on univariate analysis and general variables such as age, gender were entered into multiple logistic regression model. Rates of local control, disease-free survival, and overall survival were estimated by the Kaplan-Meier method. Comparisons of survival distributions were performed using the log-rank test. Multivariate analysis with Cox proportional hazard model was used to determine the independent predictive factors significantly impacting survival including clinical and pathologic findings. Statistical analysis was performed using SPSS ver. 18.0 (SPSS, Chicago, IL, USA).

4. Ethics statement
This study was approved and exempted of permission by the Institutional Review Board of Samsung Medical Center, Sungkyunkwan University (IRB no. 2011-04-084).

Results

1. Patient characteristics
Patient and tumor characteristics at baseline are listed in Table 1. There was no significant difference between the anemic and non-anemic patients, except that there was a tendency of anemic patients having more advanced disease at diagnosis. The median follow-up period was 44.0 months (ranges, 8.0 to 100.0 months). The median age was 55 years (range, 25 to 76 years), and a total of 53 (21.5%) and 194 (78.5%) patients were diagnosed with clinical stage II (lymph node negative) and stage III (lymph node positive) disease, respectively. About half of the patients received concurrent chemotherapy based on 5-fluorouracil (48.6%) and the other half received capecitabine (51.4%). The majority of patients (76.5%) underwent low
Table 1. Characteristics of patients and tumors

| Characteristic                                | All patients (n = 247) | Patients without anemia (n = 158) | Patients with anemia (n = 89) | p-value$^a$ |
|-----------------------------------------------|------------------------|-----------------------------------|------------------------------|-------------|
| Age (yr)                                       |                        |                                   |                              |             |
| ≤60                                           | 161 (65.2)             | 106 (67.2)                        | 55 (67.2)                    | 0.408       |
| >60                                           | 86 (34.8)              | 52 (32.8)                         | 34 (28)                      |             |
| Gender                                        |                        |                                   |                              | 0.779       |
| Male                                          | 166 (67.2)             | 105 (66.0)                        | 61 (68.4)                    |             |
| Female                                        | 81 (32.8)              | 53 (34.0)                         | 28 (31.6)                    |             |
| Distance from anal verge (cm)                 |                        |                                   |                              | 0.572       |
| ≤5                                            | 169 (68.4)             | 106 (66.9)                        | 63 (76.5)                    |             |
| >5                                            | 78 (31.6)              | 52 (33.1)                         | 26 (23.5)                    |             |
| Initial CEA level (ng/mL)                     |                        |                                   |                              | 0.351       |
| ≤5                                            | 189 (76.5)             | 124 (78.8)                        | 65 (76.5)                    |             |
| >5                                            | 58 (23.5)              | 34 (21.2)                         | 24 (23.5)                    |             |
| Anemia before NACRT                           |                        |                                   |                              |             |
| Yes                                           | 89 (36.0)              | -                                 | -                            |             |
| No                                            | 158 (64.0)             | -                                 | -                            |             |
| Concurrent chemotherapy                       |                        |                                   |                              | 0.602       |
| 5-Fluorouracil                                | 120 (48.6)             | 75 (47.1)                         | 45 (51.7)                    |             |
| Capecitabine                                  | 124 (50.2)             | 80 (49.4)                         | 44 (50.6)                    |             |
| Capecitabine + oxaliplatin                    | 3 (1.2)                | 3 (1.9)                           | 0 (0.5)                      |             |
| Clinical T stage                              |                        |                                   |                              | 0.016       |
| cT2                                           | 8 (3.2)                | 4 (2.5)                           | 4 (4.5)                      |             |
| cT3                                           | 214 (86.7)             | 144 (90.5)                        | 70 (80.9)                    |             |
| cT4                                           | 25 (10.1)              | 10 (6.3)                          | 15 (16.8)                    |             |
| Clinical N stage                              |                        |                                   |                              | 0.054       |
| cN0                                           | 53 (21.5)              | 40 (25.4)                         | 13 (14.6)                    |             |
| cN+                                           | 194 (78.5)             | 118 (74.6)                        | 76 (85.4)                    |             |
| Type of surgery                               |                        |                                   |                              | 0.051       |
| Sphincter-preserving surgery$^b$              | 203 (82.2)             | 131 (83.1)                        | 64 (71.9)                    |             |
| APR$^b$                                       | 44 (17.8)              | 27 (16.9)                         | 25 (28.1)                    |             |
| Circumferential resection margin              |                        |                                   |                              |             |
| Positive                                      | 13 (5.3)               | 8 (5.1)                           | 5 (5.6)                      |             |
| Negative                                      | 234 (94.7)             | 150 (94.9)                        | 84 (94.4)                    |             |
| Post-CRT pathologic T stage                   |                        |                                   |                              | 0.142       |
| ypT0                                          | 46 (18.6)              | 36 (22.5)                         | 10 (11.3)                    |             |
| ypT1                                          | 4 (1.6)                | 4 (2.5)                           | 0 (0.0)                      |             |
| ypT2                                          | 10 (4.0)               | 7 (4.4)                           | 3 (3.4)                      |             |
| ypT3                                          | 64 (25.9)              | 38 (24.2)                         | 26 (29.2)                    |             |
| ypT4                                          | 115 (46.7)             | 68 (43.4)                         | 47 (52.8)                    |             |
| Post-CRT pathologic N stage                   |                        |                                   | 0.818                        |
| ypN0                                          | 177 (71.7)             | 114 (71.9)                        | 63 (70.8)                    |             |
| ypN1                                          | 51 (20.6)              | 31 (19.5)                         | 20 (22.5)                    |             |
| ypN2                                          | 19 (7.7)               | 13 (8.3)                          | 6 (6.8)                      |             |
| Post-CRT M stage                              |                        |                                   | 0.715                        |
| ypM0                                          | 239 (96.8)             | 152 (96.9)                        | 87 (96.6)                    |             |
| ypM1                                          | 8 (3.2)                | 6 (3.1)                           | 2 (2.4)                      |             |
anterior resection (LAR) of the rectum. The median pretreatment Hb level was 13.5 g/dL (range, 7.0 to 17.7 g/dL). Among the 247 patients, 89 (36.0%) patients had anemia before treatment. In the present study, Hb level was corrected in 10 patients with levels less than 8.0 to 9.0 g/dL according to institutional policy; however, all patients remained anemic during radiotherapy.

Eight patients developed distant metastasis to the liver after NACRT. All these patients received resection of the primary and metastasectomy or radiofrequency ablation of the metastatic tumors. Complete resection was performed in 234 patients; 13 (5.3%) patients had a positive circumferential resection margin (CRM).

### 2. Tumor response and anemia

Pathological tumor staging was ypT0 in 46 (18.6%), ypTis in 4 (1.6%), ypT1 in 10 (4.0%), ypT2 in 64 (25.9%), ypT3 in 115 (46.6%), and ypT4 in 8 (3.2%) patients. Tumor downstaging and nodal downstaging was achieved in 133 (23.8%) patients, respectively (Table 1). Complete response was achieved in 42 (17.0%) patients based on pathologic examination. Predictors of pCR on univariate analysis were found to be female gender ($p = 0.041$) and anemia before treatment ($p = 0.015$) (Table 2). Multivariate analysis showed that pretreatment anemia remained significant factor for predicting pCR after NACRT ($p = 0.012$) (Table 2).
Table 3. Results of univariate and multivariate analyses of factors affecting local control

| Variable | Univariate LC at 3 yr (%) | p-value | Multivariate Hazard ratio | 95% CI | p-value |
|----------|--------------------------|---------|---------------------------|-------|---------|
| Age (yr) | ≤60 vs. >60              | 91.1/94.6 | 0.311                   | 0.564 | 0.181-1.762 | 0.325 |
| Gender   | Female vs. Male          | 92.1/92.9 | 0.546                   | 1.059 | 0.397-2.824 | 0.909 |
| Distance from anal verge (cm) | ≤5 vs. >5     | 92.4/91.8 | 0.908                   | -     | -         | -     |
| Initial CEA level (ng/mL)      | ≤5 vs. >5     | 91.7/94.1 | 0.508                   | -     | -         | -     |
| Anemia before NACRT No vs. Yes | 95.7/86.0 | 0.005 | 2.952                   | 1.076-8.094 | 0.035 |
| Clinical T stage cT2-3 vs. cT4     | 93.4/80.7 | 0.028 | 1.780                   | 0.560-5.655 | 0.329 |
| Clinical N stage cN0 vs. cN+ | 95.9/91.2 | 0.544 | -                       | -     | -         | -     |
| Circumferential resection margin Negative vs. Positive | 92.7/84.6 | 0.246 | -                       | -     | -         | -     |
| Post-CRT pathologic T stage ypT0-2 vs. ypT3-4 | 99.2/84.8 | <0.001 | 6.005                   | 1.328-27.143 | 0.020 |
| Post-CRT pathologic N stage ypN0 vs. ypN+ | 96.4/80.8 | 0.001 | 2.881                   | 1.093-7.598 | 0.032 |

LC, local control; CEA, carcinoembryonic antigen; CI, confidence interval; NACRT, neoadjuvant concurrent chemoradiotherapy.

Fig. 1. Local control rate in patients with pretreatment anemia vs. non-anemic patients.

3. Univariate and multivariate survival analysis of clinico-pathologic variables associated with local control

Three- and five-year overall survival (OS) rate was 90.1% and 81.1%, respectively. Disease-free survival (DFS), distant metastasis-free survival (DMFS) and local control rate at three years were 77.8%, 80.1%, and 92.9%, respectively.

Improved local control was significantly associated with clinical tumor stage (p = 0.028), pathologic tumor stage (p < 0.001), and pathologic node stage (p = 0.001) on univariate survival analysis (Table 3). Although positive CRM was not significantly associated with local control (p = 0.246), a trend towards decreased overall survival was observed (p = 0.075). The presence of anemia before radiotherapy was significantly associated with reduced probability of local control based on univariate survival analysis (p = 0.005) (Fig. 1), although no significant differences in DMFS, DFS, or OS were observed on the basis of Hb level.

In multivariate analysis, the Cox proportional analysis showed that anemia had a significant adverse effect on local control after NACRT and surgery for rectal cancer (hazard ratio, 2.95; 95% confidence interval, 1.076 to 8.094; p = 0.035) (Table 3).

Discussion and Conclusion

Anemia is frequently present in patients during the course of cancer. It may be a presenting sign of malignancy or a consequence of anticancer therapy. Harrison et al. reported that anemia, when defined at Hb level of <2.0 g/dL, is relatively common in patients presenting for radiotherapy with an estimated incidence of up to 40–60% [13]. During radiotherapy, the prevalence of anemia increases to up to...
80% depending on tumor type [13]. As locally advanced rectal cancers may benefit from a combination of chemotherapy and radiotherapy, anemia may represent an important factor hindering favorable clinical outcomes.

Numerous studies have found anemia to be a predictor of poor local control and survival at various sites of malignancy including rectal cancer. Box et al. [14] demonstrated that non-anemic patients achieved better tumor response and less local recurrence (7% vs. 38%, p = 0.003) and improved OS (91% vs. 61%, p = 0.021) than anemic patients. Berardi et al. [15] also showed that DFS was worse in patients with Hb ≤12.0 g/dL compared to those with Hb >12.0 g/dL (p = 0.018). Rades et al. [16] found that locally recurrent rectal cancer patients with Hb levels ≥12.0 g/dL had significantly better local control than those with levels <12.0 g/dL (p < 0.001). Hb levels ≥12.0 g/dL were also associated with significantly better survival in their study (p = 0.031). Our results were consistent with these studies showing that pretreatment anemia could affect the clinical outcome in Korean patients as well. Although Lee et al. [17] also investigated the predictive role of anemia in Korean patients treated with NACRT, in that they focused on whether anemia influences the pathologic response, our results showed further that it could be one of prognostic factor affecting local control.

The most important prognostic factor affecting local control and survival is tumor extent, which is commonly evaluated based on the Tumor-Node-Metastasis staging system. Our data also confirmed that pathologic tumor and nodal stages influenced local control, DFS, and OS (ypT: p < 0.001 for local control, p < 0.001 for DFS, p = 0.006 for OS; ypN: p = 0.001 for local control, p < 0.001 for DFS, p = 0.001 for OS). However, the influence of Hb level was only for local control in our study presenting no significant differences in DFS and OS between anemic and non-anemic patients (3-year DFS: 75.7% vs. 79.0%, p = 0.355; 3-year OS: 89.0% vs. 90.7%, p = 0.767). It seems that higher local control in non-anemic patients does not directly translate into improved OS because the majority of failure patterns were distant metastases (51 of 247 patients, 20.6%) rather than local recurrences (18 of 247 patients, 7.3%).

Besides the negative impact on response to radiotherapy, anemia itself is also an important factor to be considered during treatments. Since anemia is a major cause of fatigue, and fatigue is the most common symptom in cancer patients resulting in decreased quality of life, recognizing and correcting anemia is important for quality of life improvement in cancer patients [18-20]. In most clinical settings, severe anemia is treated with red blood cell transfusions, but mild-to-moderate anemia has been usually neglected. However, the early correction of anemia up to an Hb level of 12.0 to 14.0 g/dL may improve both local control as well as quality of life.

There are numerous methods to correct anemia, including iron supplements, transfusion of packed red blood cells, and/or the administration of erythropoietin-stimulating agents (ESAs). ESAs were initially used to treat anemia in patients with chronic renal failure, including those on hemodialysis. Recent clinical trials have established that ESAs are also effective in raising Hb levels, decreasing the need for transfusions and subsequently improving quality of life in patients with cancer-related and chemotherapy-induced anemia [18,21,22]. While there is general agreement that ESAs are not indicated in anemic cancer patients who are not receiving chemotherapy [22], the use of ESAs in patients receiving radiotherapy remains controversial. Although the effectiveness of ESAs on survival was not demonstrated by a recent randomized clinical trial for head and neck cancer patients undergoing radiotherapy [23,24], our data suggest that similar trials might be needed for rectal cancer patients.

In conclusion, we propose that pretreatment anemia represents an independently predictive factor for local control in patients with rectal cancer undergoing NACRT and surgery and exerts an adverse effect on treatment results. A prospective validation of Hb level as a predictive factor is mandatory.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

References
1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 1982;69:613-6.
2. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-82.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
4. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007;246:693-701.
5. Dunst J, Kuhnt T, Strauss HG, et al. Anemia in cervical cancers:

Hyebin Lee, et al
Anemia and neoadjuvant CCRT for rectal cancer

Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys 2003;56:778-87.

6. Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-83.

7. Tanvyeton T, Choudhury AM. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer 2006;106:1554-9.

8. Pradier O, Lederer K, Hille A, et al. Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter. J Cancer Res Clin Oncol 2005;131:261-9.

9. MacRae R, Shyr Y, Johnson D, Choy H. Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 2002;64:37-40.

10. Neuhof D, Neumayer F, Einbeck W, et al. Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta Oncol 2005;44:168-73.

11. Zenda S, Hironaka S, Boku N, et al. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 2008;21:195-200.

12. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747-50.

13. Harrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing chemotherapy: prognostic significance and treatment. Oncology 2002;63 Suppl 2:11-8.

14. Box B, Lindsey I, Wheeler JM, et al. Neoadjuvant therapy for rectal cancer: improved tumor response, local recurrence, and overall survival in nonanemic patients. Dis Colon Rectum 2005;48:1153-60.

15. Berardi R, Braconi C, Mantello G, et al. Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Ann Oncol 2006;17:1661-4.

16. Rades D, Kuhn H, Schultze J, et al. Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys 2008;70:1087-93.

17. Lee SD, Park JW, Park KS, et al. Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis 2009;24:1451-8.

18. Littlewood TJ, Bajetta E, Nortier JW, Vecchione M, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.

19. Vogelzang NJ, Beerthart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34:4-12.

20. Park HC, Janjan NA, Mendoza TR, et al. Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2009;75:775-81.

21. Cella D, Bron D. The effect of Epoetin alfa on quality of life in anemic cancer patients. Cancer Pract 1999;7:177-82.

22. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.

23. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.

24. Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 2009;27:5751-6.